Preparation and identification of anti-transforming growth factor β1 U1 small nuclear RNA chimeric ribozyme in vitro

Ji-Sheng Lin, Yu-Hu Song, Xin-Juan Kong, Bin Li, Nan-Zhi Liu, Xiao-Li Wu, You-Xin Jin

AIM: To study the preparation and cleavage activity of anti-transforming growth factor (TGF)β1 U1 small nuclear (sn) RNA chimeric hammerhead ribozymes in vitro.

METHODS: TGFβ1 partial gene fragment was cloned into T-vector at the downstream of T7 promoter. 32P-labeled TGFβ1 partial transcripts as target RNA were transcribed in vitro and purified by denaturing polyacrylamide gel electrophoresis (PAGE). Anti-TGFβ1 ribozymes were designed by computer, then synthetic ribozyme fragments were cloned into the U1 ribozyme vector pZeoU1EcoSpe containing U1 snRNA promoter/enhancer and terminator. 35p-labeled U1 snRNA chimeric ribozyme transcripts were gel-purified, incubated with target-RNAs at different conditions and autoradiographed after running denaturing PAGE.

RESULTS: Active U1snRNA chimeric ribozyme (U1Rz803) had the best cleavage activity at 50 °C; at 37 °C, it was active, Kcat=34.48 nmol/L, K0.1=0.14 min⁻1; while the point mutant ribozyme U1Rz803m had no cleavage activity, so these indicated the design of U1Rz803 was correct.

CONCLUSION: U1Rz803 prepared in this study possessed the perfect specific catalytic cleavage activity. These results indicate U1 snRNA chimeric ribozyme U1Rz803 may suppress the expression of TGFβ1 in vivo, therefore it may provide a new avenue for the treatment of liver fibrosis in the future.

INTRODUCTION

The incidence of liver cirrhosis is still high all over the world, especially in China[7-12]. Cirrhotic livers are characterized by extensive fibrosis throughout the entire hepatic parenchyma[7-12]. Many factors inducing liver injury and inflammation will lead to chronic liver disease, and hepatic fibrosis[13-22].

TGFβ1 is an important cytokine in the regulation of the production, degradation, accumulation of extracellular matrix proteins, and that it may play a pivotal role in the fibroproliferative changes that follow tissue damage in many vital organs and tissues, including liver, lung, kidney, skin, heart, and arterial walls[17, 23-27]. In the past decade dramatic advances have been made in the understanding of cellular and molecular mechanisms underlying liver fibrogenesis, it is thought that TGFβ1 is of crucial importance in rat hepatic fibrosis in vivo[7, 28-34]. Inhibition of TGFβ1 can not only prevent liver fibrosis, but also preserve organ function[35, 36]. So TGFβ1 has been thought to be an ideal target molecule to prevent the progression of liver fibrosis.

Ribozymes are a class of small catalytic RNA molecules that recognize specific substrate RNA molecules by their complementary nucleotide sequence, cleaving the substrate RNA as an endoribonuclease at enzymatic rates[35-38]. In the last years ribozyme-mediated inhibition of gene expression in intact cells have been tested many times, but some of them were largely unsuccessful[39-42]. Factors that contributed to ribozyme efficacy in transfected cell are expression level, stability against rapid degradation, correct folding for exposure to target, and subcellular localization of ribozyme and target. U1 snRNA is a highly expressed stable small RNA (164 nucleotides) involved in both splicesome and catalytic processing during pre-mRNA splicing. U1 small nuclear RNA expression cassette can provide an excellent vehicle for ribozyme delivery and expression in intact cell because of stability, nuclear localization, highly efficient expression[43-49]. Because TGFβ1 plays a crucial role in liver fibrosis, in this study we designed ribozymes directed against TGFβ1 by computer, then cloned them into U1 snRNA chimeric ribozyme vector, it had been proven that it could cleave target RNA efficiently in vitro through the cleavage reaction, so it indicated that it might suppress intracellular TGFβ1 expression, which would provide a new avenue in treatment of liver fibrosis.

MATERIALS AND METHODS

Materials

HSC-T6 cell line is a kind gift from Dr. Scott L. Friedman (Dept of Medicine and Division of Liver Diseases, Mount Sinai School of Medicine). pZeoU1EcoSpe was provided by Dr. Harry C. Dietz (Department of Pediatrics, Medicine and Molecular Biology & Genetics, Johns Hopkins University School of Medicine). pGEM-T vector kit, transcription kit were purchased from Promega Company. Trizol kit, DMEM were purchased from Gibco BRL Company. The PCR primers and ribozyme fragments were synthesized in the Beckman oligo-1 000 DNA synthesizer. Zeocin was purchased from Invitrogen Company. Newborn calf serum was purchased from Hyclone Company. RT-PCR kit, RNase inhibitor, restriction endonucleases, and T4 DNA ligase were purchased from Takara Company. α-P32 UTP was purchased from Beijing Ya-Hui Company.
Methods

Construction of target RNA in vitro
Total RNA was extracted using Trizol Kit (GIBCO BRL) from cultured HSC-T6 cell, an immortalized rat hepatic stellate cells line (HSC), exhibited an activated phenotype[46,47]. The upstream primer P1 (5’-GAATTCATTCAGGACTATCACCTACC-3’) in the untranslated region and the downstream primer P2 (5’-AAGCTTTTCTGGTAGAGTTCTACGTG-3’) in the open reading frame were selected to amplify a 651-base pair fragment corresponding to bases 279 to 930 of the rat TGF beta 1[48]. The extracted RNA was reversely transcribed and polymerase chain reaction (PCR) amplified using a pair of primers in one step reverse transcriptase (RT) PCR kit. The PCR products were analyzed and purified on 1 % (w/v) agarose gels. Purified PCR products were ligated into pGEM-T vector. DNA sequencing results showed that the PCR-amplified fragments were cloned into the molecular cloning sites of pGEM-T vector at the downstream of T7 promoter as pTGF beta 1. Target RNA was prepared through in vitro transcription of PCR-amplified products of pTGF beta 1, which contained T7 promoter at the upstream of upper primer. The sequence of the primers for transcription was GAATTC TAATACGACTCACTATAGGG AGGCGGA-CTACTACGCCAA and TTCTGGTAGAGTTCTACGTG; TAATACGACTCACTAG GG represents T7 promoter. Then PCR product was analyzed and purified by 1 % (w/v) agarose gels electrophoresis as the template for transcription. In vitro transcription was carried out at 37 °C for 90 min in a 40 µL final volume containing 40 mmol/L of Tris·HCl (pH 7.5), 5 mmol/L of DTT, 2 mmol/L of spermidine, 8 mmol/L of MgCl2, 0.25 mmol/L of ATP, GTP, CTP, 0.05 mmol/L of UTP, 20 µCi alpha 32p-UTP, 80 U T7 RNA polymerase and 2 µg purified PCR product. Target RNA was purified by 6 % denaturing gel electrophoresis through cutting off the autoradiograph bands and soaking in NES (0.5 mol/L NH4Ac, 0.1 mol/L EDTA, 0.1 % SDS pH 5.4) at 42 °C overnight. The products were precipitated by ethanol, washed twice by 75 % ethanol, dissolved in DEPC H2O and reserved under -20 °C.

Construction of recombinant plasmid for ribozyme
pZeoU1EcoSpe contained the pZeoSV plasmid DNA modified by excising the SV40 promoter, SV40 polyadenylation site, and poly linker at the BamHI sites. In constructing the pZeoU1 EcoSpe, a U1 snRNA expression cassette in pUC13[49, 50] was excised with BamHI digestion and ligated into the BamHI sites of the modified pZeoSV. Two rounds of site-directed mutagenesis were then performed to change 4 nt flanking the Sm protein binding site of U1 snRNA, creating unique EcoRI and SpeI restriction sites. The 5’-flanking region of the inserted U1 snRNA expression cassette possessed a promoter/enhancer comparable in strength with the SV40 early promoter[51]. The ribozymes for TGFβ1 were designed according to the computer software pcFOLD combiled by professor Zuker (Canadian Academy of Science). The homologous possibility with the gene of rat was excluded by consulting with RNA sequence of rat cells from NCBI Genbank. The enclosed vector pZeoU1EcoSpe was cut by EcoRI and SpeI restriction enzymes and purified by 1 % (w/v) agarose gels electrophoresis. The synthesized oligonucleotides of ribozyme were mixed with equal molar amounts together, then were cloned into the EcoRI/SpeI sites of pZeoU1EcoSpe to create pU1Rz803. pZeoU1EcoSpe and the reconstruction could be confirmed by DNA sequencing (Figure 1). The oligonucleotides of Rz803 were 5’-AATTACATATATACT (GA)ATGAGTCCGTAGGAAACCTTGTA3’ and 5’-CTAGACACAGTTTCGTCCTCACGGACACTCAT (CT) AGTATATATGT3’; G and C for activated ribozyme, A and T for inactivated ribozyme.

Figure 1 Sequence and predicted structure of U1 snRNA chimeric ribozymes. arrows represent cleavage site and inactivating mutation.
Preparation of ribozymes in vitro. The templates used for transcription of U1 snRNA chimeric ribozymes were obtained by PCR amplification of pU1Rz803. The primers used for transcription were as follows: upstream primer: 5'-GAATTCTAATACGACTCAAATATAAGGGTGGCAGGGGAGA-3'; downstream primer: 5'-CAGGGAACCGCAAGCAGCAGA-3'; TAAATACGACTCACTATAGGG represents T7 promoter. The purification of PCR products was the same as that of the template for target RNA. In vitro transcription and purification of ribozyme were done as described above.

In vitro cleavage reaction of U1Rz803 and U1Rz803<sub>m</sub>. U1Rz803, U1Rz803<sub>m</sub>, and target RNA were quantified by measuring their radioactive cpm in 1 µL solution. The cleavage reaction was carried out in 5 µL solution containing 50 mmol/L Tris·HCl (pH 7.5), 20 mmol/L MgCl<sub>2</sub> and target RNA was 1:1 (molar ratio). Substrate (S) and products (P) which were cut off from substrate (S) and products (P) which were cut off from substrate (S) and products (P) which were cut off from substrate (S). Substrate concentration was held constant at 5 nmol/L and described above at 37 °C. The ribozyme concentration was 120 min; (III) the condition as (II), U1Rz803 was incubated with target RNA at different temperatures and at different times. The ribozyme was shown to be capable of cleaving target RNA in vitro. It could cleave target RNA (220 nt) efficiently and exactly to produce two fragments of 93 nt/127 nt, while U1Rz803<sub>m</sub> showed no in vitro cleavage efficacy after 120 min (Figure 3), even at Rz:S=5:1 (data not shown). At a 1:1 U1Rz803-to-S molar ratio, the cleavage efficiency (CE) was calculated under the condition of 37 °C and 120-minute reaction time, CE=51.36 %. At a 1:5 U1Rz803-to-S molar ratio, CE=27.81 %. This result indicated that the cleavage efficiency increased with increase of ribozyme concentration. The temperature and time would affect the cleavage efficiency.

RESULTS

Identification of transcription of target RNA and ribozyme. The length of target RNA transcribed from PCR-amplified template should be 220 nt. In this study the ribozymes were embedded into U1 snRNA, but stem-loop structures of U1 snRNA were maintained. Therefore, the transcripts of PCR-amplified template included U1 snRNA and ribozyme, the transcripts of U1snRNA chimeric ribozyme should be 205 nt. These results (Figure 2) were inconsistent with our design and proven to be correct.

In vitro cleavage reaction of U1Rz803 and U1Rz803<sub>m</sub>. The cleavage result showed that U1Rz803 was capable of cleaving target RNA in vitro. It could cleave target RNA (220 nt) efficiently and exactly to produce two fragments of 93 nt/127 nt, while U1Rz803<sub>m</sub> showed no in vitro cleavage efficacy after 120 min (Figure 3), even at Rz:S=5:1 (data not shown). At a 1:1 U1Rz803-to-S molar ratio, the cleavage efficiency (CE) was calculated under the condition of 37 °C and 120-minute reaction time, CE=51.36 %. At a 1:5 U1Rz803-to-S molar ratio, CE=27.81 %. This result indicated that the cleavage efficiency increased with increase of ribozyme concentration. The temperature and time would affect the cleavage efficiency.

Figure 3 Cleavage of U1Rz803 and U1Rz803<sub>m</sub> in vitro. 1: Target RNA, 2: target RNA incubated with U1Rz803, 3: target RNA incubated with U1Rz803<sub>m</sub>. The ribozymes (205 nt) were shown in this figure because the transcripts were incorporated into α<sup>p-UTP</sup> in the preparation of ribozymes.

Cleavage activity of U1Rz803 in vitro.

Temperature course. When the ratio of U1Rz803 to target RNA was 1:1 (molar ratio), the reaction mixture was incubated at different temperatures for 90 minutes. The optimal temperature was 50 °C, the cleavage efficacy increased at higher temperatures ranging from 0 °C to 50 °C, but when the temperature was above 50 °C, the cleavage efficacy decreased because the combination of ribozyme and target RNA was weakened (Figure 4).

![Figure 4](image-url) Temperature curve of the cleavage reactions of U1Rz803 prepared in vitro.

Time course. The cleavage mixture (Rz:substrate=1:5 mol·L<sup>-1</sup>) were incubated at 37 °C for different times, it was shown that the reaction product increased with increase in incubation time and it was linear within 60 min, CE<sub>max</sub>=27.81 % (Figure 5).

The kinetics of cleavage reaction. Under the condition of 37 °C and 20-minute reaction time the cleavage efficiency was calculated at Rz:S=1:2, 1:4, 1:8, 1:16 and 1:32 (mol/L) ratio. K<sub>m</sub> and K<sub>cat</sub> were obtained by the Lineweaver-Burke method (Figure 6) K<sub>m</sub>=34.48 nmol/L, K<sub>cat</sub>=0.14 min<sup>-1</sup>.
Linear Kinetic Plots of Cleavage Reaction for U1Rz803

Figure 5: Time course. (A) Specific cleavage of target RNA by U1Rz803 in vitro at 37 °C for different times. Lane 1: substrate control; lane 2: incubated for 10 min; lane 3: 20 min; lane 4: 40 min; lane 5: 60 min; lane 6: 90 min; lane 7: 120 min. (B) Time course of cleavage reactions of U1Rz803 prepared in vitro.

DISCUSSION

Hepatic fibrosis is a common response to chronic liver injury from many causes, including alcohol, persistent viral infection and hereditary metal overload. To date, reversing the causative agent is the only effective therapy to stop or even reverse the liver fibrosis, but the efficacy is limited. Therefore, the development of effective antifibrotic therapies represents a challenge for modern hepatology. With the knowledge on molecular mechanism underlying pathological fibrosis expanding, there are many antifibrotic therapies based on sound biological mechanisms have been carried out. Ueki et al injected a mix of a haemagglutinating virus of Japan (HVJ) liposomes and a plasmid containing the complementary DNA for human hepatocyte growth factor (HGF) into the gluteus muscle of rats treated with dimethylnitrosamine (DMN), a model of persistent liver fibrosis, that could produce the resolution of fibrosis in the cirrhotic liver[32], but tumorigenicity found in transgenic mice overexpressing HGF[33] and repetitive in vivo transfection are two disadvantages. Qi and Nakamura et al prevent liver fibrosis from blockade of TGF beta signal by adenovirus-mediated local expression of a dominant negative type II TGF-beta receptor in the liver of rats treated with DMN, this intervention not only suppressed fibrosis, but also facilitated hepatocyte regeneration, however prolonged period of blocking TGF beta signal could result in unfavorable consequences, such as the inflammation and tissue necrosis[30,33]. Because TGFβ1 plays a crucial role in liver fibrosis and no report on anti-TGFβ1 ribozyme-mediated cleavage of target RNA for the treatment of liver fibrosis has been published, in this study we designed ribozyme targeting against TGFβ1 and cloned the ribozyme genes into U1 ribozyme vector, prepared U1 snRNA chimeric ribozymes and identified the cleavage activity of ribozymes in vitro.

In the previous study on cleavage activity of U1 snRNA chimeric ribozyme in vitro, ribozymes were prepared through the transcription of synthesized ribozyme genes containing T7/SP6 promoter, the transcripts only included ribozyme[30], but ribozyme structure induced by the secondary structure of long flanking sequences would affect ribozyme’s turnover ratio and/or binding activity as the results of less accurate hybridization and less cleavage. In this study we prepared ribozyme by the PCR-amplified templates. The transcripts included U1 snRNA and ribozyme. Compared with the previous study, it may reflect the cleavage activity of U1Rz803 more accurately in vivo. From our study, we found that the cleavage activity of U1 sn RNA chimeric ribozyme was inferior to that of non-modified ribozyme, the result was not shown in this paper. Trimethylguanosine 5’ cap, stable stem-loop structures at both end, high GC content of 3’ loop in the structure of U1 snRNA confer resistance to exonucleases in vivo[54]. The hypermethylation of the 5’ cap structure and Sm binding site enable U1 snRNA to accumulate in the nucleoplasm, these make U1 snRNA an effective vector for efficient expression and delivery of ribozyme in the nuclear compartment in vivo. The transcripts of ribozyme labeled by isotope not only provided convenience for us to isolate ribozyme by cutting off autoradiograph bands, but the transcripts were qualified more accurately than non-labeled transcripts of ribozymes. In this study Km and Kcat of U1Rz803 were measured at 37 °C, not at optimal temperature. Because the ribozyme is used in vivo and the temperature in vivo is constant at 37 °C, these results may reflect cleavage activity of U1Rz803 in physiological condition.

Ribozymes have all the properties of antisense RNA with the additional feature of catalytic cleavage. To separate antisense from cleavage effect, we created inactive ribozymes by substituting an essential nucleotide of the catalytic core with
an inactive one. The cleavage reaction revealed that U1Rz803
possessed the perfect cleavage activity, while U1Rz803α
possessed no catalytic activity. It can be used as control
to exclude antisense effect of ribozyme in vivo in order that it
is proven that the activity of U1Rz803 is due to catalytic cleavage
in vivo. The kinetics of U1Rz803 showed that U1Rz803
possessed perfect specific ability of cleaving the TGFβ1
transcripts in vitro. These results made U1Rz803 to be worthy
of being studied in intact cell and be developed as a nucleic
acid drug in the future. However the in vitro result cannot
completely reflect in vivo performance. The secondary and
tertiary structure formed by the total TGF beta 1 mRNA
transcript in the cell, the subcellular compartment which the
ribozyme and target are located in, degradation of ribozyme,
the complexes which are formed by ribozyme and
ribonucleoprotein within cell and gene delivery system affect
expression of ribozyme and cleavage activity of ribozyme. So
in vivo effect of the ribozyme should be investigated as soon
as possible. Experimental analysis of activity of the anti-TGF-
beta1 ribozyme in HSC-T6 cell is in progress.

ACKNOWLEDGEMENTS
We thanks Mr. F Xu, Mr. G Jiang, Mr.XL Chen, Mr.J Jia, Mr.
ZW Wang and Miss Li W for their kind help.

REFERENCES
1  Zhu YH, Hu DR, Nie QH, Liu GD, Tan ZX. Study on activation
c-and f-c-Jun expression of in vitro cultured human hepatic
stellate cells. Shijie Huaren Xluaohu Zazhi 2000; 8: 299-302
2  Du WD, Zhang YE, Zhai WR, Zhou XM. Dynamic changes of
type I, III and IV collagen synthesis and distribution of collagen-
producing cells in carbon tetrachloride-induced rat liver fibrosis.
World J Gastroenterol 1998; 4: 206-209
3  Huang ZG, Zhai WR, Zhang YE, Zhang XR. Study of heteroserum-induced rat liver fibrosis model and its mechanism.
World J Gastroenterol 1998; 4: 206-209
4  Jia JB, Tan DW, Xu RL, Gao F, Zhao LF, Zhao YC, Yan JP, Ma
XH. Effect of endotoxin on fibroinectin synthesis of rat primary
cultured hepatocytes. World J Gastroenterol 1998; 4: 329-331
5  Cheng ML, Wu YY, Huang KF, Luo TY, Ding YS, Lu YY, Liu RC,
Wu J. Clinical study on the treatment of liver fibrosis due to hepatic
fibrosis quantification. Shijie Huaren Xluaohu Zazhi 1998; 8:
307-309
6  Nie QH, Cheng YQ, Xie YM, Zhao YX, Cao YZ. Inhibiting effect of
anti sense oligonucleotides phosphorothioate on gene expression
of TIMP-1 in rat liver fibrosis. World J Gastroenterol 2001; 7:
363-369
7  Friedman SL. The cellular basis of hepatic fibrosis: mechanism
and treatment strategies. N Engl J Med 1993; 328: 1828-1835
8  Wang X, Chen YX, Xu CF, Zhao GN, Xu QL. Relationship between
liver fibrosis and age in rat liver fibrosis. World J Gastroenterol 1998; 4:
307-309
9  Xu LX, Xue XC, Jin R, Ji ZH, Wu ZZ, Wang ZZ. Effect of selenium
in rat experimental liver fibrosis. Huaren Xluaohu Zazhi 1998; 6:
133-135
10  Li DG, Lu HM, Chen YW. Studies on anti-liver fibrosis of
trandine. Shijie Huaren Xluaohu Zazhi 1999; 7: 171-172
11  Wu YA, Kong XY. Anti-hepatic fibrosis effect of pentoxifylline.
Shijie Huaren Xluaohu Zazhi 1999; 7: 265-266
12  Liu F, Liu X, Cao CZ, Li BS, Zhao CY, Kong L, Zhen Z. Relationship
between TGF-β1 serum indexes of liver fibrosis and hepatic-tissue
pathology in patients with chronic liver diseases. Shijie
Huaren Xluaohu Zazhi 1999; 7: 519-521
13  Gu SW, Luo KX, Zhang L, Wu AH, He HT, Weng JY. Relationship
between ductular proliferation and liver fibrosis of chronic liver
disease. Shijie Huaren Xluaohu Zazhi 1999; 7: 945-947
14  Li BS, Wang J, Zhen YJ, Liu JX, Wei MX, Sun SQ, Wang SQ.
Experimental study on serum fibrosis markers and liver tissue
pathology and hepatic fibrosis in immune damaged rats. Shijie
Huaren Xluaohu Zazhi 1999; 7: 1031-1034
15  Wang Y, Gao Y, Huang YQ, Yu JL, Fang SG. Gelatinase a proen-
zyme expression in the process of experimental liver fibrosis. Shijie
Huaren Xluaohu Zazhi 2000; 8: 165-167
16  Wang FS, Wu ZZ. Current situation in studies of gene therapy
for liver cirrhosis and liver fibrosis. Shijie Huaren Xluaohu Zazhi 2000;
8: 371-373
17  Wang GQ, Kong XT. Action of cadf and decorin in tissue
fibrosis. Shijie Huaren Xluaohu Zazhi 2000; 8: 455-460
18  Liu F, Wang XM, Liu JX, Wei MX. Relationship between serum
TGF-β1 of chronic hepatitis B and hepatic tissue pathology and
hepatic fibrosis quantification. Shijie Huaren Xluaohu Zazhi 2000; 8:
528-531
19  Li JC, Ding SP, Xu J. Regulating effect of Chinese herbal medi-
cine on the peritoneal lymphatic stomata in enhancing ascites
absorption of experimental hepatofibrotic mice. World J Gastroenterol 2002; 8: 333-337
20  Olaso E, Friedman SL. Molecular regulation of hepatic fibrogenesis.
J Hepatol 1998; 29: 836-842
21  Pinari M, Marra F, Cardoni V. Signal transduction in hepatic stell-
ate cells. Liver 1998; 18: 2-13
22  Alcolado R, Arthur MIP, Iredale JP. Pathogenesis of liver fibrosis.
Clin Sci 1997; 92: 103-112
23  Massague J. The transforming growth factor-beta family. Annu
Rev Cell Biol 1990; 6: 597-641
24  Sporn MB, Robert AB. Transforming growth factor-beta: recent
progress and new challenges. J Cell Biol 1992; 117: 1017-1021
25  Border WA, Noble NA. Transforming growth factor-beta in tis-
 sue fibrosis. N Engl J Med 1994; 331: 1269-1272
26  Heldin CH, Miyazono K, ten Dijke P. TGF-beta-signal in cell
membrane to nucleus through SMAD proteins. Annu Rev Cell
t Biol 1996; 12: 457-470
27  Miyazono K. TGF-beta-receptors and signal transduction. Int J
Hematol 1997; 65: 97-104
28  Friedman SL. Molecular regulation of hepatic fibrosis, an inte-
grated cellular response to tissue injury. J Biol Chem 2000;
275: 22271-22280
29  Bissell DM, Rouldt D, George J. Transforming growth factor and liver.
Hepatology 2001; 34: 859-867
30  Qi Z, Atsushi N, Ooshima A, Takeshita A, Ueno H. Blockade of
type beta transforming growth factor signaling preventing liver
fibrosis and dysfunction in the rat. Proc Natl Acad Sci 1999;
96: 2345-2349
31  Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield
L, Roberts AB, Sporn MB, Thorgeirsson SS. Hepatic expression
of TGF-β1 in cultured rat primary liver fibroblasts. J Biol Chem
1998; 273: 34717-34720
32  Ukci T, Kameda Y, Tsutsui H, Nakashiki K, Sawa Y, Morishita R,
Matsumoto K, Nakamura T, Takahashi H, Okamoto E, Fujimoto
J. Hepatocyte growth factor gene therapy for liver cirrhosis in rats.
Nat Med 1999; 5: 226-230
33  Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of
transforming growth factor beta prevents progression of liver
fibrosis and enhances hepatocyte regeneration in dimethylhydra-
sine-treated rats. Hepatology 2000; 32: 247-255
34  Ueno H, Sakamato T, Nakamura T, Qi Z, Astuchi N, Takeshita
A, Shimizu K, Ohashi H. A soluble transforming growth factor
beta receptor expressed in muscle prevents liver fibrogenesis and
dysfunction in rats. Hum Gene Ther 2000; 11: 33-42
35  Persidis A. Ribonucleases. Nat Biotechnol 1997; 15: 921-922
36  Gibson SA, Shillitoe EJ. Ribozymes. Their functions and strate-
gies for their use. Curr Opin Biotechnol 1997; 7: 125-137
37  James HA, Gibson I. The therapeutic potential of ribozymes. Blood
1998; 91: 371-382
38  Muotri AR, da Veiga Pereira L, dos Reis Vasques L, Mendk CF.
Ribozymes and the anti-gene therapy: how a catalytic RNA can
be used to inhibit gene function. Gene 1999; 237: 303-310
39  von Weizsacker F, Blum HE, Wands JR. Cleavage of hepatitis B
virus RNA by three ribozymes transcribed from a single DNA
template. Biochen Biophys Res Commun 1992: 189: 743-748
40  Beck J, Nassal M. Efficient hammerhead ribozyme-mediated
cleavage of the structured hepatitis B virus encapsidation signal
in vitro and in cell extracts, but not in intact cells. Nucleic Acids
Res 1995; 23: 4954-4962
41 Xu RH, Liu J, Zhou XQ, Xie Q, Jin YX, Yu H, Liao D. Activity identification of anti-caspase-3 mRNA hammerhead ribozyme in both cell-free condition and BRL-3A cells. Chin Med J 2001; 114: 606-611

42 Xu RH, Liu J, Xu F, Jiang G, Xie Q, Zhou XQ, Jin YX, Wang DB. Activity identification of chimeric anti-caspase-3 mRNA hammerhead ribozyme in vitro and in vivo. Science China(C) 2001; 44: 618-627

43 Liu R, Li W, Karin NJ, Bergh JJ, Adler-Storthz K, Farach-Carson MC. Ribozyme ablation demonstrates that the cardiac subtype of the voltage-sensitive calcium channel is the molecular transducer of 1, 25-dihydroxyvitamin D3-stimulated calcium influx in osteoblastic cells. J Biol Chem 2000; 275: 8711-8718

44 Montgomery RA, Dietz HC. Inhibition of fibrillin 1 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence. Hum Mol Genet 1997; 6: S19-S25

45 Michienzi A, Prislei S, Bozzoni I. U1 small nuclear RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus. Proc Natl Acad Sci 1996; 93: 7219-7224

46 Vogel S, Plantedosi R, Frank J, Lalazar A, Rockey DC, Friedman SL, Blaner WS. An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J Lipid Res 2000; 41: 882-893

47 Kim Y, Ratziu V, Choi SG, Lalazar A, Theiss G, Dang Q, Kim SJ, Friedman SL. Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem 1998; 273: 33750-33758

48 Qian SW, Kondaiah P, Roberts AB, Sporn MB. cDNA cloning by PCR of rat transforming growth factor beta-1. Nucleic Acids Res 1990; 18: 3059

49 Manser T, Gesteland RF. Characterization of small nuclear RNA U1 gene candidates and pseudogenes from the human genome. J Mol Appl Genet 1981; 1: 117-125

50 Zhuang Y, Weiner AM. A compensatory base change in U1 snRNA suppresses a 5’ splice site mutation. Cell 1996; 46: 827-835

51 Skuzeski JM, Lund E, Murphy JT, Steinberg TH, Burgess RR, Dahlberg JE. Synthesis of human U1 RNA. II. Identification of two regions of the promoter essential for transcription initiation at position +1. J Biol Chem 1984; 259: 8345-8352

52 Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature 1987; 328: 596-600

53 Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci 1997; 94: 701-706

54 Green MR. Biochemical mechanisms of constitutive and regulated pre-mRNA splicing. Annu Rev Cell Biol 1991; 7: 559-599

Edited by Wu XN